Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1996-11-01
2000-06-13
Arthur, Lisa B.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 915, 514866, C12Q 168, C12P 1934
Patent
active
060748222
ABSTRACT:
A test method and test kit for determining a risk of diabetic complications based upon abnormal aldose reductase genetic material expression is described. Cells isolated from a patient which exhibit elevated levels of aldose reductase genetic material expression at pathophysiologic levels of glucose (about 20 mM) which can occur commonly in the cells of diabetic patients are evaluated based upon a level of expression of DNA or RNA in the cells with the glucose at the pathophysiologic level. The cells can be used to isolate DNA or RNA for a probe which detects the abnormal aldose reductase gene expression. The method can be used to determine when particular aldose reductase inhibitors can be effective for a particular patient.
REFERENCES:
Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment & Research on Gene Therapy pp. 1-38, 1995.
Correll et al. Human Gene Therapy. 1:277-287, 1990.
Paillard. Human Gene Therapy 8:2009-2010, 1997.
James. Antiviral Chemistry & Chemotherapy 2(4):191-214, 1991.
Westermann et al. Biomed. Biochim. Acta 1:85-93, 1989.
Stevens et al. Am J. Physiol. 265(Endocrinol. Metab. 28): E428-E438, 1993.
Henry et al. J Am Soc. Nephrol. 6(3):362, Sep. 1995.
Ruepp et al. Proc. Natl. Acad. Sci. 93:8624-8629, Aug. 1996.
Graham et al. J. Biol. Chem. 266:6872-6877, Apr. 1991.
Stratagene Calatog 1988, p. 39, 1988.
Jones et al, eds RNA Isolation and Analysis BIOS Scientific Publishers pp. 95-109, 128, 133-143, 1994.
Bigler et al. Clin. Res. 37(1):A127, Jan. 1989.
Nishimura et al. Diabetologia 37:328-330, Mar. 1994.
Shah et al. J. Amer. Soc. Nephrol. 5(3):384, Sep. 1994.
Henry et al J. Clin. Invest. 92:617-623, Aug. 1993.
Wang et al. J. Biol. Chem. 268:16052-16058, Jul. 1993.
Ko et al. Diabetes 44:727-732, Jul. 1995.
Tomlinson et al. Trends in Pharmacol. Sci 15:293-297, Aug. 1994.
Hamada et al. Diabetes 40:1233-1240, Oct. 1991.
Sun, Y., et al Variability in the Structure & Expression of the Aldose REductase (AR) Gene Modulates the Risk for Diabetic Nephropathy, JASN vol. 7, No. 9 (1996) (Abstract).
Shah, V.O., et al, Aldose REductase Gene Expression Is Increased in Diabetic Nephropathy, Journal of clinical Endocrinology and Metabolism 82:229402298 (1997).
Patel, A., et al, Chromosome 7q35 and Susceptibility to Diabetic Microvascular Complications, Journal of Diabetes and its Complications 10:62-67 (1996).
Heesom, AE, et al Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 46(2):287-291 (1997) (Abstract).
Kicic E, Palmer, Increased white cell aldose reductase mRNA levels in diabetic patients. Diabetic Res. Clin Pract 33(1):31-36 (1996) (Abstract).
Ito, T., et al The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy? Diabetes Res Clin. Pract. 36(3):161-167) (Abstract).
Arthur Lisa B.
Board of Trustees operating Michigan State University
McLeod Ian C.
Souaya Jehanne
LandOfFree
Method for testing for risk of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for testing for risk of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for testing for risk of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2067434